Characterization of a Ligand-attenuated Binding Site on Glycoprotein IIb/IIIa

Summary

We describe an epitope on the platelet integrin, GPIIb/IIIa, identified by the monoclonal antibody, 4F8, which is attenuated by small-molecule GPIIb/IIIa ligands. 4F8 did not bind to the ligand binding pocket as it did not compete with a radiolabelled antagonist, ³H-SC-52012. This indicates that the 4F8 epitope behaves as a ligand-attenuated binding site (LABS). Ligand-induced attenuation of 4F8 was an active process as it was prevented by pretreating platelets with cytochalasin D and reduced by prostaglandin E1 or inhibition of protein kinase C. Disappearance of the epitope was required for full platelet activation as 4F8 prevented platelet aggregation without inhibiting fibrinogen binding. These results suggest a model where disappearance of the 4F8 epitope is a secondary event required for full “outside-in” signaling through GPIIb/IIIa.

Keywords

Integrin - glycoprotein IIb/IIIa - conformational change - platelet - thrombosis

• References

• 1 Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Medicinal Res Reviews 1994; 14: 195-228.
• 2 Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biological Chemistry 1985; 260: 11107-14.
• 3 Huang M, Lipfert L, Cunningham M, Brugge J, Ginsberg M, Shattil S. Adhesive ligand binding to integrin alpha IIb beta 3 stimulates tyrosine phosphorylation of novel protein substrates before phosphorylation of pp125FAK. J Cell Biology 1993; 122: 473-83.
• 4 Shattil S, Haimovich B, Cunningham M, Lipfert L, Parsons J, Ginsberg M, Brugge J. Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors. J Biological Chemistry 1994; 269: 14738-45.
• 5 Aoki T, Tomiyama Y, Honda S, Senzaki K, Tanaka A, Okubo M, Takahashi F, Takasugi H, Seki J. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA₂ synthesis. Thromb Haemost 1998; 79: 1184-90.
• 6 O’Toole T, Mandelman D, Forsyth J, Shattil S, Plow E, Ginsberg M. Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science 1991; 254: 845-7.
• 7 Stephens G, O’Luanaigh N, Reilly D, Harriott P, Walker B, Fitzgerald D, Moran N. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J Biol Chem 1998; 273: 20317-22.
• 8 Honda S, Tomiyama Y, Pelletier AJ, Annis D, Honda Y, Orchekowski R, Ruggeri Z, Kunicki TJ. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biological Chemistry 1995; 270: 11947-54.
• 9 Kouns W, Wall C, White M, Fox C, Jennings L. A conformation-depen-0dent epitope of human platelet glycoprotein IIIa. J Biol Chem 1990; 265: 20594-601.
• 10 Frelinger A, Du XP, Plow E, Ginsberg M. Monoclonal antibodies to ligandoccupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biological Chemistry 1991; 266: 17106-11.
• 11 Mondoro TH, Wall CD, White MM, Jennings LK. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood 1996; 88: 3824-30.
• 12 Humphries MJ. Integrin cell adhesion receptors and the concept of agonism. TiPS 2000; 21: 29-32.
• 13 Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using two monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-8.
• 14 McGregor J, McGregor L, Lyons M, Bauer A, Huppert J. Identification of the fibrinogen binding sites on chymotrypsin treated human blood platelets using a monoclonal antibody. Thromb Haemost 1985; 54: 236 (Abstr).
• 15 Phillips D, Fitzgerald L, Parise L, Steiner B. Platelet membrane glycoprotein IIb-IIIa complex: Purification, characterization, and reconstitution into phospholipid vesicles. Methods in Enzmology 1992; 215: 244.
• 16 Medelsohn M, Zhu Y, O’Neill S. The 29-kDa Proteins Phosphorylated in Thrombin-Activated Human Platelets are Forms of the Estrogen Receptor-Related 27-kDa Heat Shock Protein. PNAS 1991; 88: 11212-6.
• 17 Fullard J, Murphy R, O’Neill S, Moran N, Ottridge B, Fitzgerald DJ. A Val193Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. Brit J Haematology 2001; 115: 131-9.
• 18 Zablocki JA, Miyano M, Garland RB, Pireh D, Schretzman L, Rao SN, Lindmark RJ, Panzer-Knodle SG, Nicholson NS, Taite BB, Salyers A, King L, Campion J, Feigen L. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Argguanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor. J Medicinal Chemistry 1993; 36: 1811-9.
• 19 Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. JBC 2000; 275.
• 20 Shcherbina A, Remold-O’Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999; 93: 4222-31.
• 21 Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992; 80: 2539-47.
• 22 Shattil S, Ginsberg M. Integrin signaling in vascular biology. J Clinical Investigation 1997; 100: S91-5.
• 23 Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO 1998; 17: 6622-32.
• 24 Miyamoto S, Katz B, Lafrenie R, Yamada K. Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. Annals of the New York Academy of Sciences 1998; 857: 119-29.
• 25 Miranti C, Leng L, Maschberger P, Brugge J, Shattil S. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1. Current Biology 1998; 08: 1289-99.
• 26 Lipfert L, Haimovich B, Schaller M, Cobb B, Parsons J, Brugge J. Integrindependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biology 1992; 119: 905-12.
• 27 Leisner TM, Wencel-Drake JD, Wang W, Lam SC. Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations. JBC 1999; 274: 12945-9.
• 28 Mould AP, Akiyama SK, Humphries MJ. The inhibitory anti-beta1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function. J Biological Chemistry 1996; 271: 20365-74.
• 29 Cierniewski CS, Byzova T, Papierak M, Haas TA, Niewiarowska J, Zhang L, Cieslak M, Plow EF. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses. J Biol Chem 1999; 274: 16923-32.
• 30 Aguirre JGhiso, Farias E, Alonso D, Arregui C, Bal de Kier EJoffe. A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and beta1-integrin point contact distribution. Int J Cancer 1997; 71: 881-90.
• 31 D’Souza S, Ginsberg M, Lam S, Plow E. Chemical cross-linking of arginylglycyl-aspartic acid peptides to an adhesion receptor on platelets. J Biol Chem 1988; 263: 3943-51.
• 32 Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (IIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
• 33 Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, Matsuzawa Y. Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. Blood 1998; 92: 3675-83.